Sisram Medical, an Israeli company that makes laser-based aesthetic devices, will raise up to $200 million by conducting an IPO on the Hong Kong Exchange. Sisram is a subsidiary of Shanghai Fosun Pharma. In 2013, Fosun teamed up with Chindex, which would become a Fosun subsidiary, and a private equity firm to pay $240 million for 96% of Israel’s Alma Lasers. The holding company is named Sisram. The IPO will value Sisram at up to $800 million, with Fosun owning a 66% stake.
